{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:50:57Z","timestamp":1781650257271,"version":"3.54.5"},"reference-count":29,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Hydroxychloroquine (HCQ) is frequently used to manage cutaneous manifestations associated with idiopathic inflammatory myopathies (IIMs). Nevertheless, the literature lacks consensus regarding the efficacy and safety of drugs for these manifestations. Methods: A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. The search spanned the period from January 1958 to April 2025 across the following databases: PubMed, Scopus, Web of Science, Cochrane Library, PsycInfo, and Virtual Health Library. Articles were included if they contained at least one of the specified descriptors in the title or abstract; were published in English, Portuguese, or Spanish; and addressed the use of HCQ or chloroquine (CQ) in the context of skin manifestations of IIMs. Review articles, experimental studies, and short communication articles were excluded. Results: Among the 319 patients assessed, the majority were women diagnosed with dermatomyositis or juvenile dermatomyositis. The most prevalent cutaneous manifestations were Gottron\u2019s papules and diffuse erythematous lesions. The most frequent extracutaneous manifestations were muscle weakness and arthritis\/arthralgia. HCQ was administered in 74% of the cases, with dosages ranging from 200 to 400 mg\/day and a follow-up duration of 26 months. In most cases, it is administered in conjunction with glucocorticoids. Adverse effects were observed in less than 9% of the patients, with myalgia, skin lesions, and photosensitivity being the most common. However, the use of CQ has not been documented in any of these studies. Conclusions: Although there are studies in the literature using HCQ as part of the treatment of cutaneous manifestations in patients with IIMs, longitudinal studies with larger sample sizes and more robust methods are required to evaluate the applicability of HCQ in the treatment of IIMs.<\/jats:p>","DOI":"10.3390\/ph18091293","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:08:52Z","timestamp":1756458532000},"page":"1293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Hydroxychloroquine Useful for the Treatment of Cutaneous Manifestations of Idiopathic Inflammatory Myopathies? A Systematic Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-7959","authenticated-orcid":false,"given":"Jucier","family":"Gon\u00e7alves J\u00fanior","sequence":"first","affiliation":[{"name":"School of Medicine, Universidade Federal do Cariri (UFCA), Barbalha 63180-000, Cear\u00e1, Brazil"},{"name":"School of Medicine, Universidade Regional do Cariri (URCA), Crato 63105-000, Cear\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6049-0697","authenticated-orcid":false,"given":"Jamily Izabel Alves dos","family":"Santos","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidade Federal do Cariri (UFCA), Barbalha 63180-000, Cear\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Katsuyuki","family":"Shinjo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de S\u00e3o Paulo, S\u00e3o Paulo 01246-903, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/B978-0-323-98818-6.00023-6","article-title":"Autoimmune inflammatory myopathies","volume":"195","author":"Dalakas","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13023-022-02382-x","article-title":"The health-related quality of life, mental health and mental illnesses of patients with inclusion body myositis (IBM): Results of a mixed methods systematic review","volume":"17","author":"Senn","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","first-page":"e115","article-title":"Idiopathic inflammatory myopathies: Current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.6061\/clinics\/2013(05)07","article-title":"Chloroquine diphosphate: A risk factor for herpes zoster in patients with dermatomyositis\/polymyositis","volume":"68","author":"Cunha","year":"2013","journal-title":"Clinics"},{"key":"ref_6","first-page":"2","article-title":"Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies","volume":"15","author":"Dugan","year":"2009","journal-title":"Dermatol. Online J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/1744666X.2023.2270737","article-title":"A comprehensive review of dermatomyositis treatments\u2014From rediscovered classics to promising horizons","volume":"20","author":"Sevim","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.31138\/mjr.29.4.221","article-title":"68-year old woman with refractory cutaneous dermatomyositis","volume":"4","author":"Antopoulos","year":"2018","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2025.01.043","article-title":"Diffuse erythema with \u2018\u2018angel wings\u2019\u2019 sign in Belgian patients with anti small ubiquitin-like modifier activating enzyme antibody- associated dermatomyositis","volume":"60","author":"Dens","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_10","first-page":"1","article-title":"Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies","volume":"15","author":"Dugan","year":"2009","journal-title":"Dermatol. Online J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","article-title":"Dermatomyositis: An Update on Diagnosis and Treatment","volume":"21","author":"Cobos","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_12","first-page":"53","article-title":"Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review","volume":"2","author":"Shinjo","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10633-015-9521-y","article-title":"A possible early sign of hydroxychloroquine macular toxicity","volume":"132","author":"Brandao","year":"2016","journal-title":"Doc. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D329562407","article-title":"A case series of hydroxychloroquine exacerbating the dermatomyositis rash","volume":"29","author":"Rypka","year":"2023","journal-title":"Dermatol. Online J."},{"key":"ref_15","first-page":"1031","article-title":"A Brazilian registry of juvenile dermatomyositis: Onset features and classification of 189 cases","volume":"27","author":"Sato","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jdcr.2019.07.024","article-title":"A unique case of dermatomyositis associated with anti-TIF1g antibody and chondrosarcoma","volume":"5","author":"Dziwis","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"2","author":"Oldroyd","year":"2022","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdcr.2021.04.017","article-title":"Antimelanoma differentiation-associated gene 5 dermatomyositis associated with acute encephalopathy","volume":"13","author":"Nguyen","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamadermatol.2018.2549","article-title":"Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_20","first-page":"287","article-title":"Successful management of a 7-year-old female with juvenile dermatomyositis at a tertiary hospital in a low-income country","volume":"6","author":"Wulandari","year":"2024","journal-title":"Paediatr. Indones."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10067-003-0807-1","article-title":"Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: A case of Wong\u2019s dermatomyositis","volume":"23","author":"Caporali","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_22","first-page":"434","article-title":"Juvenile dermatomyositis","volume":"7","author":"Ishaque","year":"2011","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_23","first-page":"158","article-title":"Adverse cutaneous reaction to hydroxychloroquine in a patient with anti-SAE-1-positive dermatomyositis and a history of diffuse large B-cell lymphoma","volume":"37","author":"Pruneda","year":"2024","journal-title":"Bayl. Univ. Med. Cent."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2021.01.035","article-title":"Lagophthalmos as a presenting sign in dermatomyositis with muscle involvement limited to the ocular muscles","volume":"10","author":"Roesler","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12026-022-09334-4","article-title":"Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzymes: A report of 4 cases from North India and a review of literature","volume":"71","author":"Vignesh","year":"2023","journal-title":"Immunol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4078\/jrd.2020.27.4.285","article-title":"Dermatomyositis Presenting as Life-threatening Hypercalcemia","volume":"27","author":"Chiu","year":"2020","journal-title":"J. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/acr2.11605","article-title":"Higher odds of adverse cutaneous reactions in patients with dermatomyositis treated with hydroxychloroquine compared with methotrexate","volume":"5","author":"Allenzara","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e234111","DOI":"10.1136\/bcr-2019-234111","article-title":"Ovoid palatal patch: A clue to anti- TIF1\u03b3 dermatomyositis.al","volume":"13","author":"Franciosi","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41927-021-00195-2","article-title":"Mechanic\u2019s hand; is it a prodromic sign of disease relapse of anti-synthetase syndrome; a case report","volume":"5","author":"Rosa","year":"2021","journal-title":"BMC Rheumatol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:01Z","timestamp":1760034901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ph18091293"],"URL":"https:\/\/doi.org\/10.3390\/ph18091293","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}